Save

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

PHASE1PHASE2RECRUITING

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.

Simpliy with AI

Study details:

Enrollment of subjects into Phase 1 will proceed concurrently by age as follows:. * Subjects \<12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group; once the pediatric RP2D is determined, subjects age \<12 years old may be enrolled into the Phase 2 part of the study. * Subjects 12 to 25 years old will be directly enrolled into the Phase 2 part concurrent with Phase 1 enrollment.

Phase 1:. Approximately 12 pediatric subjects with locally advanced or metastatic solid tumors, including a primary central nervous system (CNS) tumor, or anaplastic large cell lymphoma (ALCL), with disease progression or who are non-responsive or intolerant to available therapies and for which no standard or available curative therapy exists. Phase 2:.

Subjects will be enrolled in one of 3 cohorts as follows:. Cohort 1: approximately 10-20 subjects with solid tumors characterized by NTRK fusion, TRK tyrosine kinase inhibitor (TKI)-naïve, and centrally confirmed measurable disease at baseline. Cohort 2: approximately 23 subjects with solid tumors characterized by NTRK fusion, TRK TKI-pretreated, and centrally confirmed measurable disease at baseline.

Cohort 3: approximately 20 subjects with solid tumors or ALCL characterized by other ALK/ROS1/NTRK alterations or NTRK fusions without centrally confirmed measurable disease not otherwise eligible for Cohort 1 or 2. As of the current protocol amendment, only patients with ROS1 alterations will be enrolled to this cohort.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.

Phase 1: Age <12 years; Phase 2: Age 12- 25 years

Prior cytotoxic chemotherapy is allowed.

Prior immunotherapy is allowed.

Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment.

Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment.

Subjects must have a Lansky (< 16 years) or Karnofsky (≥ 16 years) score of at least 50.

Life expectancy greater than or equal to 12 weeks, in the investigator's opinion.

Adequate hematologic, renal and hepatic function.

Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment.

Exclusion criteria

Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.

Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.

Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).

Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.

Any of the following cardiac criteria:

Peripheral neuropathy of CTCAE ≥grade 2.

Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.

Any potential allergies to repotrectinib and/or its excipients.

Simplify with AI

Eligibility

Age eligible for study : 0 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2020-03-12

Primary completion: 2026-09-30

Study completion finish: 2027-09-30

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT04094610

Intervention or treatment

DRUG: Oral repotrectinib (TPX-0005)

Conditions

• Lymphoma
• Locally Advanced Solid Tumors
• Metastatic Solid Tumors
• Primary CNS Tumors

Condition: Lymphoma, Locally Advanced Solid Tumors and more
DRUG: Oral repotrectinib (TPX-0005)
South Brisbane, Queensland, Australia and more
Sponsor: Turning Point Therapeutics, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Children's Health Queensland Hospital and Health Service

Research sites nearby

Select from list below to view details:

Children's Health Queensland Hospital and Health Service
South Brisbane, Queensland, Australia
Local Institution - 6104
Randwick, New South Wales, Australia
Local Institution - 6103
Westmead, New South Wales, Australia
Perth Childrens Hospital
Nedlands, Western Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Repotrectinib (TPX-0005) Phase 1 Oral repotrectinib (TPX-0005): Safety and tolerability at different dose levels Phase 2 Oral repotrectinib (TPX-0005): 3 cohorts Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ROS1 gene fusions or other ROS1 aberrations	DRUG: Oral repotrectinib (TPX-0005) Oral repotrectinib (TPX-0005)

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Dose limiting toxicities (DLTs) (Phase 1)	Define the dose limiting toxicities (DLTs) (Phase 1)	Within 28 days of the first repotrectinib dose
Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)	To determine the pediatric RP2D (Phase 1)	Within 28 days of the last patient dosed in escalation
Overall Response Rate (ORR) (Phase 2)	To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)	Two to three years after first dose of repotrectinib

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall Response Rate (ORR) (Phase 1)	To determine the overall response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)	Approximately three years
Clinical Benefit Rate (CBR) (Phase 1 and Phase 2)	To determine the CBR of repotrectinib (TPX-0005) (Phase 1 and Phase 2)	Approximately three years
Time to response (TTR) (Phase 1 and Phase 2)	To determine the TTR of reprotrectinib (TPX-005) (Phase 1 and Phase 2)	Approximately three years
Duration of response (DOR) (Phase 1 and Phase 2)	To determine the DOR of repotrectinib (TPX-0005) (Phase 1 and Phase 2)	Approximately three years
Intracranial objective response rate (IC-ORR) (Phase 1 and Phase 2)	To determine the IC-ORR of repotrectinib (TPX-005) (Phase 1 and Phase 2)	Approximately three years
Central Nervous System Progression-Free Survival (CNS-PFS) (Phase 2)	CNS-PFS in subjects with measurable brain metastases (Phase 2)	Approximately three years
Progression-free survival (PFS) (Phase 2)	To determine the PFS (Phase 2)	Approximately three years
Overall survival (OS) (Phase 2)	To determine the OS (Phase 2)	Approximately three years
Maximum concentration of repotrectinib in plasma (Cmax)	To determine the Cmax	Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)
Area under the concentration versus time curve of repotrectinib in plasma (AUC)	To determine the AUC	Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations